HURA Stock — TuHURA Biosciences Inc.: Cash, EV, Pipeline

Share price

$2.10

Market cap

$133.8M

Cash

$1.0M

Enterprise value

$136.4M

Balance sheet

Cash	$1.0M
Debt	$3.6M
Net cash	-$2.6M
Enterprise value	$136.4M
Basic shares	63.7M shares
Fully diluted shares	115.1M shares
Fully diluted market cap	$241.7M
Cash per share	$0.02

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading HURA daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
May 12 - Jun 23	IFx-Hu2.0	Phase 3	Advanced Or Metastatic Merkel Cell Carcinoma	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

IFx-2.0

Phase 3 · Active Modality: plasmid DNA innate immune agonist (intratumoral)

Aliases IFx-Hu2.0

Indications

Advanced/metastatic Merkel cell carcinoma (first-line, adjunctive to pembrolizumab, checkpoint inhibitor naive) (Phase 3)
Merkel cell carcinoma / cutaneous squamous cell carcinoma (adjunctive to anti-PD(L)1) (Phase 1)
Metastatic Merkel cell carcinoma of unknown primary origin (deep-seated tumors, adjunctive to Keytruda) (Phase 1)

Catalysts

— second half of 2027

Status note Lead candidate; single randomized placebo-controlled Phase 3 registration trial initiated Jun 2025 under FDA SPA, utilizing accelerated approval pathway. Phase 1b in MCC/cSCC complete; Phase 1b/2a in MCCUP deep-seated tumors initiated May 2025.

TBS-2025

Phase 1 · Active Modality: monoclonal antibody (intravenous)

Aliases KVA12123

Target VISTA

Partnerships n/a; rights acquired via Kineta, Inc. merger (closed Jun 30, 2025)

Indications

Relapsed/refractory mutNPM1 AML (monotherapy and in combination with menin inhibitor) (Phase 1)
Advanced refractory solid tumors (Phase 1)

Catalysts

— first half of 2026
— second half of 2026

Status note Prior Phase 1 in refractory solid tumors (mono and +pembrolizumab) complete. Phase 2-ready candidate for mutNPM1 AML. Company also investigating TBS-2025 conjugated to a DOR inhibitor as a lead ADC candidate (preclinical).

IFx-3.0

Stage not disclosed · Terminated Modality: mRNA innate immune agonist (intravenous / autologous whole-cell)

Indications

Blood-related cancers (Stage not disclosed)

Status note 10-K: 'we have determined not to advance the development of IFx-3.0 until the results of the IFx-2.0 Phase 3 trial' (following the Kineta acquisition). IFx-3.0 is an mRNA innate immune agonist for blood-related cancers.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	IFx-Hu2.0
Lead indication	Advanced Or Metastatic Merkel Cell Carcinoma
Lead phase	Phase 3
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06947928	Phase 3	Recruiting	Sponsor	HURA	—	Advanced Or Metastatic Merkel Cell Carcinoma	—
NCT06940440	Phase 1	Recruiting	Sponsor	HURA	—	Advanced Or Metastatic Merkel Cell Carcinoma	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for TuHURA Biosciences, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

HURA — TuHURA Biosciences Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials